Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01336686
First received: April 14, 2011
Last updated: March 30, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2011
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 19, 2015